HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 289/4/H1669    most recent 00106.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Cullen, J. P. Articles by Redmond, E. M. Search for Related Content PubMed PubMed Citation Articles by Cullen, J. P. Articles by Redmond, E. M.

Ethanol inhibits monocyte chemotactic protein-1 expression in interleukin-1-activated human endothelial cells

¹Department of Surgery, University of Rochester Medical Center, Rochester, New York; and ²Vascular Health Research Centre, Dublin City University, Dublin, Ireland

Submitted 2 February 2005 ; accepted in final form 16 May 2005

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
The aim of this study was to determine the effect of ethanol (EtOH) on endothelial monocyte chemotactic protein-1 (MCP-1) expression. IL-1 increased the production of MCP-1 by human umbilical vein endothelial cells from undetectable levels to 900 pg/ml at 24 h. EtOH dose-dependently inhibited IL-1-stimulated MCP-1 secretion as determined by ELISA: 25 ± 1%, 35 ± 7%, and 65 ± 5% inhibition for 1, 10, and 100 mM EtOH, respectively, concomitant with inhibition of monocyte adhesion to activated endothelial cells. Similarly, EtOH dose-dependently inhibited IL-1-stimulated MCP-1 mRNA expression. Experiments with actinomycin D demonstrated that EtOH decreased the stability of MCP-1 mRNA. In addition, EtOH significantly reduced NF-B and AP-1 binding activity induced by IL-1 and inhibited MCP-1 gene transcription. Binding of ¹²⁵I-labeled MCP-1 to its receptor (CCR2) on THP-1 human monocytic cells was not affected by EtOH treatment. Modulation of the expression of MCP-1 represents a mechanism whereby EtOH could inhibit atherogenesis by blocking the crucial early step of monocyte adhesion and subsequent recruitment to the subendothelial space. These actions of EtOH may underlie, in part, its cardiovascular protective effects in vivo.

alcohol; chemokines; atherogenesis

Monocyte chemotactic protein-1 (MCP-1) is a member of the C-C chemokine family and a potent chemoattractant for monocytes (27). The involvement of MCP-1 in the pathogenesis of atherosclerosis has been widely investigated, and much evidence exists to support its central role in the process. Migration of monocytes across the endothelial barrier is a significant early event in the formation of atherosclerotic lesions. Several studies provide compelling evidence for a direct role of MCP-1 in monocyte recruitment during atherosclerosis. In response to several atherogenic stimulants such as oxidized LDL, PDGF, and IL-1, MCP-1 is induced in endothelial cells, SMC, and monocytes (31, 33). The expression of MCP-1 and other chemokines is thought to be regulated primarily at the level of gene transcription, although contributions by posttranslational mechanisms have also been reported (35). The promoter region of the MCP-1 gene contains binding sites for the redox-responsive transcription factors NF-B and AP-1 (16). MCP-1 mediates its biological activity mainly through interaction with an MCP-1 receptor, CCR2 (also known as C-C chemokine receptor) on the surface of its target cells, which include monocytes. This receptor belongs to the superfamily of G protein-coupled receptors with seven transmembrane domains. The important role of CCR2 in atherogenesis has been demonstrated in studies using gene knockout animal models; there was a marked decrease in atherosclerotic lesion formation in apolipoprotein E (apoE)-null mice that lacked CCR2 (4), and increased CCR2 expression is evident in patients with hypercholesterolemia (9). Several agents, including homocysteine and oxidized LDL, have been shown to affect CCR2 expression (37).

Although moderate alcohol consumption is correlated negatively with cardiovascular risk, the effect of EtOH on MCP-1 and its CCR2 receptor in the context of vascular disease and the molecular mechanisms involved are unknown. Here, we examined the effect of EtOH treatment on chemokine-induced MCP-1 expression in human endothelial cells in culture and on CCR2 receptor binding on THP-1 monocytes. We demonstrate that although EtOH has no effect on monocyte CCR2 binding activity it inhibits IL-1-stimulated endothelial MCP-1 expression by decreasing MCP-1 mRNA stability, NF-B and AP-1 binding activity, and MCP-1 gene transcription.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Endothelial cell isolation and culture. Endothelial cells from human umbilical veins (HUVEC) were prepared by established methods as previously described (23). Briefly, HUVEC were harvested from human umbilical veins by adding 0.1% collagenase (GIBCO Laboratories, Grand Island, NY) for 30 min. The cells were grown to confluence in medium 199 (GIBCO) supplemented with 10% heat-inactivated FCS (Flow Laboratories, McLean, VA), penicillin-streptomycin (GIBCO), fungizone (GIBCO), and endothelial cell growth factor. Cells were assessed for endothelial cell phenotype by morphology and expression of von Willebrand factor antigen and platelet endothelial cell adhesion molecule. Endothelial cells between passages 2 and 5 were used in all experiments. THP-1 cells, a human monocytic cell line, were obtained from American Type Culture Collection (ATCC, Manassas, VA). Growth medium consisted of RPMI 1640, 10% FCS, 0.05 mM 2-mercaptoethanol, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/l glucose, and 1.5 g/l bicarbonate. To avoid differentiation, cultures were maintained at a density of 2 x 10⁵ cells/ml.

EtOH treatment. Two hundred-proof EtOH (Pharmco Products, Brookfield, CT) was diluted and added to HUVEC medium to achieve desired concentrations. Cultures (70–80% confluent) were pretreated with or without EtOH for 2 h before stimulation with IL-1 (1 ng/ml), in the absence or presence of EtOH, for various times (1–24 h). To avoid evaporation of EtOH, petri dishes were immediately sealed in Parafilm. Cell viability was evaluated by Trypan blue exclusion assay and by comparing gross morphology to that of control cells. Actual levels of EtOH in culture medium over time were determined with a diagnostic kit from Sigma.

ELISA for MCP-1. Supernatants from treated HUVEC were collected and analyzed for MCP-1 protein concentration with a Chemikine human MCP-1 sandwich ELISA kit according to the manufacturer's instructions (Chemicon International, Temecula, CA).

¹²⁵I-labeled MCP-1 binding to THP-1 cells. For binding assays THP-1 cells were washed in PBS before being resuspended in binding buffer (RPMI 1640, 0.5% BSA, 25 mM HEPES, pH 7.4) at 1 x 10⁶ cells/200 µl. Cells were incubated for 90 min at 25°C with 0.02–0.4 nM ¹²⁵I-labeled MCP-1 (specific activity 2,200 Ci/mmol) in the absence or presence of 100 nM unlabeled MCP-1. The reaction was terminated by filtration of the reaction mixture through a GF/B filter (presoaked in 0.03% polyethyleneimine) with a Brandel cell harvester (Brandel Biomedical Research and Development Laboratories, Gaithersburg, MD). Radioactivity on the washed filters was counted in a gamma counter. Specific ¹²⁵I-MCP-1 binding was determined by subtracting the nonspecific binding estimated in the presence of 100 nM unlabeled MCP-1 from total binding. To determine the exact binding affinity (K_d) and the total maximum number of binding sites (B_max), the data were analyzed with Prism software (GraphPad).

Monocyte adhesion. Monocyte adherence experiments were carried out essentially as described by Chang et al. (5). THP-1 cells in RPMI 1640 medium containing 0.1% fetal bovine serum were labeled with 1 µCi of [³H]thymidine overnight (specific activity 23 Ci/mmol). THP-1 cells (6 x 10⁵) were added to each well containing control or IL-1-treated HUVEC and incubated for 1 h. Nonadherent monocytes were removed by washing with HBSS. HUVEC with adherent THP-1 cells were lysed with 1 M NaOH, and the radioactivity was counted by a scintillation counter.

Northern blot analysis. Total RNA was isolated from HUVEC with TRIzol reagent (GIBCO-BRL). Aliquots (10 µg) of the total RNA samples were separated on formaldehyde-agarose gels. The RNAs were transferred and UV cross-linked to nylon membranes and hybridized with ³²P-labeled cDNA probes for human MCP-1 and GAPDH (ATCC) that were prepared by random priming. Transcripts were quantitated by NIH Image 1.60 and normalized with GAPDH levels for equal loading.

Electrophoretic mobility shift assay. EMSA was carried out essentially as described previously (5). To extract nuclear protein, HUVEC were washed and scraped in PBS. After centrifugation, the cell pellet was resuspended in buffer A (in mM: 10 KCl, 0.1 EDTA, 1 DTT, and 1 PMSF). The cells were lysed by adding 10% NP-40 and then centrifuged to obtain nuclear pellets. The nuclear pellets were extracted in buffer B (in mM: 20 HEPES, 1 EDTA, 1 DTT, 1 mM PMSF with 0.4 M NaCl), vigorously agitated, and then centrifuged. The supernatant containing the nuclear proteins was used for the EMSA or stored at –70°C for later use. Oligonucleotides corresponding to AP-1 (5'-CGCTTGATGAGTCAGCCG-GAA-3', Promega) and consensus NF-B (5'-AGTTGAGGGGATTTTCCCAGGC-3', Promega) binding sites were end-labeled with [-³²P]ATP and T4 polynucleotide kinase. Nuclear extracts, normalized for protein content (10 µg), were incubated with 0.1 ng of ³²P-labeled DNA for 15 min at room temperature in a final volume of binding buffer of 25 µl containing 1 µg of poly(dI-dC). The mixtures were electrophoretically separated on 6% nondenaturing polyacrylamide gels under high ionic strength. Gels were dried and imaged by autoradiography.

Nuclear run-on assay. Nuclear run-on transcription analysis was performed as described previously (29). HUVEC were washed with cold PBS and lysed with 0.5% NP-40 solution. The nuclei were isolated by centrifugation and resuspended in a 40% glycerol buffer. The nuclei were incubated with [-³²P]UTP at room temperature for 30 min. The run-on RNA was purified by treating the reaction mixture with DNase I and proteinase K followed by precipitation with EtOH. The labeled RNA was hybridized to 10 µg of linearized, denatured plasmid DNA blotted on membrane in 50% (vol/vol) formamide, 0.3 M NaCl, 0.03 M sodium citrate, 0.01% Ficoll, 0.01% polyvinylpyrrolidone, 0.01% bovine serum albumin, and 0.1% SDS-100 µg of salmon sperm DNA per milliliter (hybridization buffer) at 42°C for 24 h. The same number of counts of RNA was hybridized to each filter.

Statistics. Data are means ± SE; n is the number of individual experiments, with a minimum of three independent experiments performed. Statistical significance was estimated with the following analysis: unpaired Student's t-test for comparison of two groups and Wilcoxon signed-rank test for the densitometric data. A value of P < 0.05 was considered significant.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Effect of EtOH on IL-1-stimulated MCP-1 secretion. MCP-1 was measured in medium samples by ELISA. Under basal conditions, HUVEC MCP-1 levels were undetectable. Treatment of HUVEC with IL-1 (1 ng/ml) induced MCP-1 production in a time-dependent manner (Fig. 1A). The induction of MCP-1 by IL-1 was evident as early as 1 h after treatment. At 24 h after IL-1 treatment, MCP-1 levels were generally 700–900 pg/ml. The phorbol ester PMA (10 ng/ml) also potently induced MCP-1 secretion in HUVEC (Fig. 1A) and was included for comparison purposes. EtOH (1–200 mM) dose-dependently inhibited IL-1-stimulated MCP-1 secretion, with significant inhibition (25%) observed at 1.0 mM and 90% inhibition at 200 mM (Fig. 1B). The IC₅₀ (i.e., the concentration required to cause 50% inhibition of maximal response) for EtOH was 50 mM. EtOH at all concentrations used had no significant effect on HUVEC viability as assessed by Trypan blue exclusion (data not shown). The EtOH concentration in cell culture plates over the experimental period (up to 24 h) was >90% of the original concentration. The concentration was the same in the absence or presence of endothelial cells, suggesting that no significant metabolism of EtOH was occurring.

View larger version (19K): [in this window] [in a new window]   Fig. 1. A: effect of IL-1 on monocyte chemotactic protein-1 (MCP-1) production. Human umbilical vein endothelial cells (HUVEC) were treated with IL-1 (1 ng/ml) for various periods of time. MCP-1 secretion was measured in media overlay by ELISA as described in MATERIALS AND METHODS. Gray bars, effect of the comparison substance, PMA, on HUVEC MCP-1 secretion. B: effect of ethanol (EtOH) on IL-1-stimulated MCP-1 secretion. HUVEC were pretreated with or without EtOH for 2 h before being stimulated with IL-1 (1 ng/ml, 4 h). MCP-1 levels in media overlay were measured by ELISA. Results are expressed as % of control IL-1 response. *P < 0.05 vs. IL-1 treatment alone.

Effect of EtOH on IL-1-stimulated THP-1 monocyte adhesion to HUVEC.

View larger version (14K): [in this window] [in a new window]   Fig. 2. Effect of EtOH on IL-1-stimulated THP-1 adhesion to HUVEC. [3H]thymidine-labeled THP-1 monocytes were incubated for 1 h with HUVEC monolayers pretreated with or without EtOH and then activated with or without IL-1 (1 ng/ml, 2 h) (unstim.). Adherent cells were determined as described in MATERIALS AND METHODS. The inhibitory effect of the NO donor 3-morpholinosydnonimine (SIN-1) is also shown. Data are means ± SE; n = 3. *P < 0.05 vs. control (IL-1 activated, no EtOH).

View larger version (15K): [in this window] [in a new window]   Fig. 3. A: binding of 125I-labeled MCP-1 to THP-1 monocytes. Nonspecific binding (), determined in the presence of 100-fold excess of unlabeled MCP-1, was 5–20% of the total binding (); , specific binding. B: 125I-MCP-1 binding in control (C) and EtOH-treated THP-1 cells. For these 1-point binding assays, 125I-MCP-1 was added at a concentration of 0.1 nM in the absence or presence of 100 nM MCP-1.

Effect of EtOH on IL-1-stimulated MCP-1 mRNA levels.

View larger version (66K): [in this window] [in a new window]   Fig. 4. Effect of EtOH on IL-1-stimulated MCP-1 mRNA expression. HUVEC were stimulated with IL-1 (1 ng/ml) for various periods of time in the absence or presence of EtOH. Total HUVEC RNA was isolated, and Northern blots were performed as described in MATERIALS AND METHODS. A: time course for IL-1 (1 ng/ml)-stimulated MCP-1 mRNA expression. B: inhibitory effect of EtOH on IL-1 (1 ng/ml)-stimulated MCP-1 mRNA expression over time in HUVEC. The effect of the NO donor SIN-1 on IL-1-stimulated MCP-1 mRNA expression is also shown.

View larger version (25K): [in this window] [in a new window]   Fig. 5. Effect of EtOH on the stability of MCP-1 mRNA expression. HUVEC were pretreated with or without 50 mM EtOH and then stimulated with IL-1 (1 ng/ml). The cells were further incubated for various periods of time in the presence of actinomycin D (Act D, 10 µg/ml). Total HUVEC RNA was isolated, and Northern blots were performed as described in MATERIALS AND METHODS. Top, representative Northern blot. Bottom, normalized graph (semilog plot) with values representing means of 2 separate experiments.

View larger version (31K): [in this window] [in a new window]   Fig. 6. Nuclear run-on analysis of the effect of EtOH on IL-1-mediated MCP-1 gene expression. HUVEC were stimulated with IL-1 in the absence or presence of EtOH. After 30 min nuclei were isolated, and nuclear run-on assays were performed with MCP-1, GAPDH, and -tubulin cDNA as described in MATERIALS AND METHODS. A: hybridization bands were quantified, with GAPDH and -tubulin serving as internal controls for standardization. B: normalized graph with values representing means ± SE of 3 separate experiments. *P < 0.05 vs. IL-1 treatment alone.

View larger version (25K): [in this window] [in a new window]   Fig. 7. EMSA analysis of the effect of EtOH on IL-1-mediated NF-B and AP-1 DNA binding activity. HUVEC were stimulated with IL-1 in the absence or presence of EtOH. After 60 min nuclear protein was isolated and subjected to EMSA with 32P-labeled DNA probes containing either the NF-B or AP-1 binding sites as described in MATERIALS AND METHODS. A: top, representative blot showing dose-dependent inhibition by EtOH of IL-1-stimulated NF-B/DNA binding; bottom, normalized graph with values representing means ± SE of 3 separate experiments. B: top, representative blot showing inhibition by EtOH of IL-1-stimulated AP-1/DNA binding; bottom, normalized graph with values representing means ± SE of 4 separate experiments. *P < 0.05 vs. IL-1 treatment alone.

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

Several studies provide evidence for a key role of MCP-1 in cardiovascular disease. The role of MCP-1 in human disease has been implicated by immunohistochemical studies of atherosclerotic plaques (38). Direct evidence for the atherogenic potential of macrophage MCP-1 expression was derived from a study in apoE-knockout mice (1), a well-characterized model of atherogenesis. Analysis of atherosclerotic lesions in apoE mice overexpressing a murine MCP-1 transgene, when compared with the response of control apoE-knockout mice, revealed enhanced lipid staining, increased oxidized lipid content, and increased immunostaining for macrophage cell surface markers (1). In another study, mice lacking the CCR2 receptor were crossed with apoE-knockout mice and fed a Western diet. These mice displayed a decrease in lesion size and a decrease in the number of macrophages in these lesions (4), supporting the hypothesis that MCP-1 is important in monocyte recruitment during atherosclerosis and that the process of monocyte recruitment is a major determinant of lesion size and complexity. In addition, MCP-1 can induce chemotaxis of endothelial cells and can act as a direct mediator of angiogenesis (25), a process believed to be maladaptive in the atherosclerotic plaque. There is also growing evidence that chemokines, and MCP-1 in particular, may play an important pathogenic role in other cardiovascular diseases such as myocardial ischemia (20) and congestive heart failure (2).

Despite the inverse relationship between moderate alcohol consumption and the risk of coronary heart disease and the evidence for a prominent role of MCP-1 in the pathogenesis of cardiovascular disease, only a few studies have investigated the effect of EtOH on MCP-1 expression in this context. A review of the literature to date reveals that the majority of studies investigating alcohol and MCP-1 have addressed alcoholic liver injury and investigated Kupffer cell chemokine production after alcohol intoxication (see, e.g., Refs. 3, 19, 22). Szabo et al. (30) reported that acute alcohol consumption attenuated the production of monocyte MCP-1 in response to subsequent bacterial stimulation in humans by inhibiting NF-B binding. In addition, Feng et al. (8) demonstrated in a balloon injury rabbit model that long-term consumption of red wine inhibited MCP-1 expression and reduced neointimal hyperplasia, and Estruch et al. (7) reported that daily red wine consumption decreased MCP-1 in monocytes. The authors did not determine whether this effect was mediated by the phenolic compounds or the EtOH present in the red wine and provided no information on the mechanism(s) underlying the inhibitory effect. Hypercholesterolemic rabbits that underwent balloon angioplasty and daily alcohol feeding for 10 wk exhibited an increase in lumen size, a decrease in the number of foam cells in the neointima, and reduced MCP-1 and PDGF levels compared with controls (17). Again, the molecular mechanisms underlying these effects were not addressed in that study.

MCP-1 is produced by monocytes, endothelial cells, and SMC in response to various stimuli. The level of vascular endothelial cell and SMC expression of MCP-1 has been correlated with serum MCP-1 concentration (15). MCP-1 inhibitors, acting by decreasing either agonist production or receptor expression, represent potentially innovative pharmacological tools for the prevention of cardiovascular-related diseases. Although EtOH had no effect on CCR2 receptor binding activity in monocytes, our data demonstrate a dose-dependent inhibition of IL-1 stimulated endothelial cell MCP-1 by EtOH concomitant with inhibition of monocyte adhesion to activated endothelial cells. Although the possibility exists that EtOH may also alter IL-1 binding to its receptor, resulting in decreased activation and a decreased MCP-1 response, our data support an effect of EtOH at the level of MCP-1 mRNA. As evidenced by an increased MCP-1 mRNA degradation rate in actinomycin D-treated cells, EtOH decreased the stability of MCP-1 mRNA in HUVEC. Of interest, it was reported previously that EtOH stabilizes LPS-induced TNF- mRNA in Kupffer cells (13). Thus EtOH does not appear to cause a general destabilization of induced mRNA. With nuclear run-on analysis we demonstrated that IL-1-stimulated MCP-1 gene transcription was inhibited by EtOH. Moreover, EMSA indicated reduced binding of the transcription factors NF-B and AP-1, which were previously implicated in the induction of MCP-1 (16), after EtOH treatment. Given the evidence for a key role of MCP-1 in atherogenesis, inhibition by EtOH of endothelial cell MCP-1 production in vivo would be expected to result in decreased recruitment, adhesion, and transendothelial migration of monocytes at sites of arterial injury and thus decreased atherosclerosis.

An additional mechanism for the proatherogenic effect of MCP-1 has recently emerged, namely, MCP-1 directly inducing SMC proliferation by differential activation of NF-B and AP-1 (34). Interestingly, we showed previously (10, 26) that EtOH inhibits SMC proliferation by modulating the activity and expression of cell cycle regulatory molecules. The inhibitory effect of EtOH on MCP-1 reported here thus represents a second, albeit indirect, mechanism whereby EtOH may affect SMC proliferation and thus negatively affect atherogenesis. Moreover, several studies have established a relationship between NO and chemokine production by demonstrating that NO can downregulate MCP-1 production in the endothelial cell or that increased MCP-1 production is coupled with endothelial nitric oxide synthase (eNOS) downregulation (39). In light of this, our previous study (11) demonstrating a stimulatory effect of EtOH on eNOS suggests a possible synergistic mechanism whereby EtOH could inhibit MCP-1 indirectly via stimulation of NOS activity.

"Moderate" alcohol consumption is generally considered to be in the range of one to three drinks per day (14, 18, 32), giving rise to blood alcohol levels of 5–25 mM. A blood alcohol level (BAL) of 0.1 g% is approximately equivalent to 25 mM EtOH. In alcoholics, BAL can reach in excess of 100 mM. Thus the concentrations of EtOH used in our study (1–100 mM) are physiologically relevant. Significant effects of EtOH on MCP-1 were demonstrated at concentrations as low as 1 mM. Whereas a J-shaped relationship exists between alcohol and total mortality, several studies have demonstrated a strong dose-response relationship between alcohol and cardiovascular disease (21). Of note, our data demonstrate that EtOH inhibits IL-1-induced MCP-1 production in a dose-dependent manner.

The importance of our data and their relevance to the in vivo efficacy of EtOH remain speculative. However, EtOH's inhibition of endothelial MCP-1 at transcriptional and posttranscriptional levels may represent a novel mechanism contributing to its apparent cardiovascular protective effects as supported by epidemiologic studies.

	GRANTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
This work was supported in part by grants from the National Institutes of Health (AA-12610 to E. M. Redmond, DK-47067 to J. V. Sitzmann) and by grants from the Wellcome Trust and the Health Research Board of Ireland (P. A. Cahill). J. P. Cullen is the recipient of a Scientist Development Grant from the American Heart Association.

	FOOTNOTES

 

Address for reprint requests and other correspondence: E. M. Redmond, Univ. of Rochester Medical Center, Dept. of Surgery, Box SURG, 601 Elmwood Ave., Rochester, NY, 14642-8410 (e-mail: eileen_redmond{at}urmc.rochester.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^* J. P. Cullen and S. Sayeed contributed equally to this work.

	REFERENCES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 

1. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, and Milos PM. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19: 1518–1525, 1999.[Abstract/Free Full Text]
2. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, and Gullestad L. Elevated circulating levels of C-C chemokines in congestive heart failure. Circulation 97: 1136–1143, 1998.[Abstract/Free Full Text]
3. Bautista AP. Acute alcohol intoxication and endotoxemia desensitize HIV-1 gp120-induced CC-chemokine production by Kupffer cells. Life Sci 68: 1939–1949, 2001.[CrossRef][Medline]
4. Boring L, Gosling J, Cleary M, and Charo IF. Decreased lesion formation in CCR2–/– mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894–897, 1998.[CrossRef][Medline]
5. Chang YL, Shen JJ, Wung BS, Cheng JJ, and Wang DL. Chinese herbal remedy wogonin inhibits monocyte chemotactic protein-1 gene expression in human endothelial cells. Mol Pharmacol 60: 507–513, 2001.[Abstract/Free Full Text]
6. Davda RK, Chandler J, Crews FT, and Guzman NJ. Ethanol enhances the endothelial nitric oxide synthase response to agonists. Hypertension 21: 939–943, 1993.[Abstract/Free Full Text]
7. Estruch R, Sacanella E, Badia E, Antunez E, Nicolas JM, Fernandez-Sola Rotilio D, de Gaetano G, Rubin E, and Urbano-Marquez A. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Atherosclerosis 175: 117–123, 2004.[CrossRef][Web of Science][Medline]
8. Feng AN, Chen YL, Chen YT, Ding YZ, and Lin SJ. Red wine inhibits MCP-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-fed rabbits. Circulation 100: 2254–2259, 1999.[Abstract/Free Full Text]
9. Han KH, Han KO, Green SR, and Quehenberger O. Expression of the MCP-1 receptor CCR2 is increased in hypercholesterolemia: differential effects of plasma lipoproteins on monocyte function. J Lipid Res 40: 1053–1063, 1999.[Abstract/Free Full Text]
10. Hendrickson RJ, Cahill PA, McKillop IH, Sitzmann JV, and Redmond EM. Ethanol inhibits mitogen activated protein kinase activity and growth of vascular smooth muscle cells in vitro. Eur J Pharmacol 362: 251–259, 1998.[CrossRef][Web of Science][Medline]
11. Hendrickson RJ, Cahill PA, Sitzmann JV, and Redmond EM. Ethanol enhances basal and flow-stimulated nitric oxide synthase activity in vitro by activating an inhibitory guanine nucleotide binding protein. J Pharmacol Exp Ther 289: 1293–1300, 1999.[Abstract/Free Full Text]
12. Janszky I, Mukamal KJ, Orth-Gomer K, Romelsjo A, Schenck-Gustafson K, Svane B, Kirkeeide RL, and Mittleman MA. Alcohol consumption and coronary atherosclerosis progression—the Stockholm female coronary risk angiographic study. Atherosclerosis 176: 311–319, 2004.[CrossRef][Web of Science][Medline]
13. Kishore R, McMullen MR, and Nagy LE. Stabilization of tumor necrosis factor mRNA by chronic ethanol. J Biol Chem 276: 41930–41937, 2001.[Abstract/Free Full Text]
14. Klatsky AL, Armstrong MA, and Friedman GD. Alcohol and mortality. Ann Intern Med 117: 646–654, 1992.[CrossRef][Web of Science][Medline]
15. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, Hashimoto K, Yamamoto M, Fujio H, Miura A, Ohta K, Morita H, Saito H, Emori T, Nakamura Y, Kusanao I, and Ohe T. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J 68: 671–676, 2004.[CrossRef][Web of Science][Medline]
16. Martin T, Cardarelli PM, Parry GCN, Felts KA, and Cobb RR. Cytokine induction of MCP-1 gene expression in human endothelial cells depends on the cooperative action of NF-B and AP-1. Eur J Immunol 27: 1091–1097, 1997.[Web of Science][Medline]
17. Merritt R, Guruge BL, Miller DD, Chaitman BR, and Bora PS. Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model. J Cardiovasc Pharmacol 30: 19–25, 1997.[CrossRef][Web of Science][Medline]
18. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, and Rimm EB. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348: 109–118, 2003.[Abstract/Free Full Text]
19. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, and Su GL. Activation of nuclear factor B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 30: 934–943, 1999.[CrossRef][Web of Science][Medline]
20. Ono K, Matsumori A, Furukawa Y, Igata H, Shioi T, Matsushima K, and Sasayama S. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 79: 195–203, 1999.[Web of Science][Medline]
21. Pearson TA. Alcohol and heart disease. Circulation 94: 3023–3025, 1996.[Free Full Text]
22. Pennington HL, Wilce PA, and Worrall S. Chemokine and cell adhesion molecule mRNA expression and neutrophil infiltration in lipopolysaccharide-induced hepatitis in ethanol-fed rats. Alcohol Clin Exp Res 22: 1713–1718, 1998.[CrossRef][Web of Science][Medline]
23. Redmond EM, Cahill PA, Hirsch M, Wang YN, Sitzmann JV, and Okada SS. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Thromb Haemost 81: 293–300, 1999.[Medline]
24. Rubin R. Ethanol interferes with collagen-induced platelet activation by inhibition of arachidonic acid mobilization. Arch Biochem Biophys 270: 99–113, 1989.[CrossRef][Web of Science][Medline]
25. Salcedo R, Lourdes Ponce M, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, and Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96: 34–40, 2000.[Abstract/Free Full Text]
26. Sayeed S, Cullen JP, Coppage M, Sitzmann JV, and Redmond EM. Ethanol differentially modulates the expression and activity of cell cycle regulatory proteins in rat aortic smooth muscle cells. Eur J Pharmacol 445: 163–170, 2002.[CrossRef][Web of Science][Medline]
27. Shin WS, Szuba A, and Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91–102, 2002.[CrossRef][Web of Science][Medline]
28. Shyy Y, Li Y, and Kolattukudy PE. Structure of human monocyte chemotactic protein gene and its regulation by TPA. Biochem Biophys Res Commun 169: 346–351, 1990.[CrossRef][Web of Science][Medline]
29. Shyy YJ, Hsieh HJ, Usami S, and Chien S. Fluid shear stress induces a biphasic response of human MCP-1 gene expression in vascular endothelium. Proc Natl Acad Sci USA 91: 4678–4682, 1994.[Abstract/Free Full Text]
30. Szabo G, Chavan S, Mandrekar P, and Catalano D. Acute alcohol consumption attenuates interleukin-8 (IL-8) and monocyte chemoattractant peptide-1 (MCP-1) induction in response to ex vivo stimulation. J Clin Immunol 19: 67–76, 1999.[CrossRef][Web of Science][Medline]
31. Terkeltaub R, Boisvert WA, and Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 9: 397–405, 1998.[CrossRef][Web of Science][Medline]
32. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, and Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 337: 1705–1714, 1997.[Abstract/Free Full Text]
33. Van Coillie E, Van Damme J, and Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 10: 61–86, 1999.[CrossRef][Web of Science][Medline]
34. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W, and Kreuzer J. MCP-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-B and activator protein-1. Arterioscler Thromb Vasc Biol 22: 914–920, 2002.[Abstract/Free Full Text]
35. Villarete LH and Remick DG. Transcriptional and posttranscriptional regulation of interleukin-8. Am J Pathol 149: 1685–1693, 1996.[Abstract]
36. Vogel RA. Alcohol, heart disease, and mortality: a review. Rev Cardiovasc Med 3: 7–13, 2002.[CrossRef][Medline]
37. Wang G and Karmin O. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radicals. Biochem J 357: 233–240, 2001.[CrossRef][Web of Science][Medline]
38. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, and Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88: 5252–5256, 1991.[Abstract/Free Full Text]
39. Zeiher A, Fisslthaler B, Schray-Utz B, and Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein-1 in cultured human endothelial cells. Circ Res 76: 980–986, 1995.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. Santiago, J. L. Hernandez-Cruz, M. E. Manjarrez-Zavala, R. Montes-Vizuet, D. P. Rosete-Olvera, A. M. Tapia-Diaz, H. Zepeda-Peney, and L. M. Teran Role of monocyte chemotactic protein-3 and -4 in children with virus exacerbation of asthma Eur. Respir. J., November 1, 2008; 32(5): 1243 - 1942. [Abstract] [Full Text] [PDF]

				M. Vazquez-Agell, E. Sacanella, E. Tobias, M. Monagas, E. Antunez, R. Zamora-Ros, C. Andres-Lacueva, R. M. Lamuela-Raventos, J. Fernandez-Sola, J. M. Nicolas, et al. Inflammatory Markers of Atherosclerosis Are Decreased after Moderate Consumption of Cava (Sparkling Wine) in Men with Low Cardiovascular Risk J. Nutr., October 1, 2007; 137(10): 2279 - 2284. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 289/4/H1669    most recent 00106.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Cullen, J. P. Articles by Redmond, E. M. Search for Related Content PubMed PubMed Citation Articles by Cullen, J. P. Articles by Redmond, E. M.